Initiatives to increase the prescribing of low cost generics: the case of Scotland in the international context

Brian Godman, Amanj Kurdi, Axel Leporowski, Alec Morton, Christoph Baumgärtel, Tomasz Bochenek , Joseph Fadare, Alexander Finlayson, Shazhad Hussein, Babar Khan, Marija Kalaba, Dan Kibuule, Hye-Young Kwon, Oyvind Melien, Renata CRM Nascimento, Ahmed Salem, Krijn Schiffers, Ilse Truter, Luka Voncina, Azmi Hassali

Research output: Contribution to journalArticle

Abstract

Getting the most out of the pharmaceutical budget is critical across all countries as the financial pressures on healthcare systems intensify. In this paper, we review global practice on encouraging the use of low costs generics versus branded pharmaceuticals, including patented products in the same class where care is not compromised across countries to guide future practice. Our review ranges widely across European countries as well as other high income countries, including Abu Dhabi, Japan and the USA, and other low and middle income Countries. There is a particular focus on Scotland, building on previous publications. We conclude based on multiple publications, including several case studies, that achieving efficiency in pharmaceutical spending is possible in virtually all environments, although there are examples of technologies where generic or therapeutic substitution should not be encouraged. However, there is no magic bullet to achieving full and appropriate use of generics. Countries have to be prepared to use a number of different education, economic, engineering and enforcement methods including prescribing restrictions to achieve success. Similarly, different approaches to achieve low prices for good quality generics given the considerable price differences that currently exist. The combination of low prices and increased use of generics will help achieve or attain universal healthcare, benefiting all key stakeholder groups. We conclude with a call for greater cross-country learning in pursuit of what should be a common goal for all health systems.
LanguageEnglish
JournalMedical Research Archives
Volume5
Issue number3
DOIs
Publication statusPublished - 31 Mar 2017

Fingerprint

Scotland
Drug Substitution
Costs and Cost Analysis
Pharmaceutical Preparations
United Arab Emirates
Delivery of Health Care
Magic
Budgets
Publications
Japan
Economics
Learning
Technology
Efficiency
Education
Pressure
Health
Prescribing
Costs
Pharmaceuticals

Keywords

  • co-payments
  • compulsory substitution
  • Scotland
  • reforms
  • prices
  • generics
  • prescribing restrictions

Cite this

Godman, Brian ; Kurdi, Amanj ; Leporowski, Axel ; Morton, Alec ; Baumgärtel, Christoph ; Bochenek , Tomasz ; Fadare, Joseph ; Finlayson, Alexander ; Hussein, Shazhad ; Khan, Babar ; Kalaba, Marija ; Kibuule, Dan ; Kwon, Hye-Young ; Melien, Oyvind ; Nascimento, Renata CRM ; Salem, Ahmed ; Schiffers, Krijn ; Truter, Ilse ; Voncina, Luka ; Hassali, Azmi. / Initiatives to increase the prescribing of low cost generics : the case of Scotland in the international context. In: Medical Research Archives. 2017 ; Vol. 5, No. 3.
@article{6eecbd6ffacd4cbd8e23481aa492789e,
title = "Initiatives to increase the prescribing of low cost generics: the case of Scotland in the international context",
abstract = "Getting the most out of the pharmaceutical budget is critical across all countries as the financial pressures on healthcare systems intensify. In this paper, we review global practice on encouraging the use of low costs generics versus branded pharmaceuticals, including patented products in the same class where care is not compromised across countries to guide future practice. Our review ranges widely across European countries as well as other high income countries, including Abu Dhabi, Japan and the USA, and other low and middle income Countries. There is a particular focus on Scotland, building on previous publications. We conclude based on multiple publications, including several case studies, that achieving efficiency in pharmaceutical spending is possible in virtually all environments, although there are examples of technologies where generic or therapeutic substitution should not be encouraged. However, there is no magic bullet to achieving full and appropriate use of generics. Countries have to be prepared to use a number of different education, economic, engineering and enforcement methods including prescribing restrictions to achieve success. Similarly, different approaches to achieve low prices for good quality generics given the considerable price differences that currently exist. The combination of low prices and increased use of generics will help achieve or attain universal healthcare, benefiting all key stakeholder groups. We conclude with a call for greater cross-country learning in pursuit of what should be a common goal for all health systems.",
keywords = "co-payments, compulsory substitution, Scotland , reforms, prices, generics, prescribing restrictions",
author = "Brian Godman and Amanj Kurdi and Axel Leporowski and Alec Morton and Christoph Baumg{\"a}rtel and Tomasz Bochenek and Joseph Fadare and Alexander Finlayson and Shazhad Hussein and Babar Khan and Marija Kalaba and Dan Kibuule and Hye-Young Kwon and Oyvind Melien and Nascimento, {Renata CRM} and Ahmed Salem and Krijn Schiffers and Ilse Truter and Luka Voncina and Azmi Hassali",
year = "2017",
month = "3",
day = "31",
doi = "10.18103/mra.v5i3.1071",
language = "English",
volume = "5",
journal = "Medical Research Archives",
issn = "2375-1916",
number = "3",

}

Godman, B, Kurdi, A, Leporowski, A, Morton, A, Baumgärtel, C, Bochenek , T, Fadare, J, Finlayson, A, Hussein, S, Khan, B, Kalaba, M, Kibuule, D, Kwon, H-Y, Melien, O, Nascimento, RCRM, Salem, A, Schiffers, K, Truter, I, Voncina, L & Hassali, A 2017, 'Initiatives to increase the prescribing of low cost generics: the case of Scotland in the international context' Medical Research Archives, vol. 5, no. 3. https://doi.org/10.18103/mra.v5i3.1071

Initiatives to increase the prescribing of low cost generics : the case of Scotland in the international context. / Godman, Brian; Kurdi, Amanj; Leporowski, Axel; Morton, Alec; Baumgärtel, Christoph; Bochenek , Tomasz; Fadare, Joseph; Finlayson, Alexander; Hussein, Shazhad; Khan, Babar; Kalaba, Marija; Kibuule, Dan; Kwon, Hye-Young; Melien, Oyvind; Nascimento, Renata CRM; Salem, Ahmed; Schiffers, Krijn; Truter, Ilse; Voncina, Luka; Hassali, Azmi.

In: Medical Research Archives, Vol. 5, No. 3, 31.03.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Initiatives to increase the prescribing of low cost generics

T2 - Medical Research Archives

AU - Godman, Brian

AU - Kurdi, Amanj

AU - Leporowski, Axel

AU - Morton, Alec

AU - Baumgärtel, Christoph

AU - Bochenek , Tomasz

AU - Fadare, Joseph

AU - Finlayson, Alexander

AU - Hussein, Shazhad

AU - Khan, Babar

AU - Kalaba, Marija

AU - Kibuule, Dan

AU - Kwon, Hye-Young

AU - Melien, Oyvind

AU - Nascimento, Renata CRM

AU - Salem, Ahmed

AU - Schiffers, Krijn

AU - Truter, Ilse

AU - Voncina, Luka

AU - Hassali, Azmi

PY - 2017/3/31

Y1 - 2017/3/31

N2 - Getting the most out of the pharmaceutical budget is critical across all countries as the financial pressures on healthcare systems intensify. In this paper, we review global practice on encouraging the use of low costs generics versus branded pharmaceuticals, including patented products in the same class where care is not compromised across countries to guide future practice. Our review ranges widely across European countries as well as other high income countries, including Abu Dhabi, Japan and the USA, and other low and middle income Countries. There is a particular focus on Scotland, building on previous publications. We conclude based on multiple publications, including several case studies, that achieving efficiency in pharmaceutical spending is possible in virtually all environments, although there are examples of technologies where generic or therapeutic substitution should not be encouraged. However, there is no magic bullet to achieving full and appropriate use of generics. Countries have to be prepared to use a number of different education, economic, engineering and enforcement methods including prescribing restrictions to achieve success. Similarly, different approaches to achieve low prices for good quality generics given the considerable price differences that currently exist. The combination of low prices and increased use of generics will help achieve or attain universal healthcare, benefiting all key stakeholder groups. We conclude with a call for greater cross-country learning in pursuit of what should be a common goal for all health systems.

AB - Getting the most out of the pharmaceutical budget is critical across all countries as the financial pressures on healthcare systems intensify. In this paper, we review global practice on encouraging the use of low costs generics versus branded pharmaceuticals, including patented products in the same class where care is not compromised across countries to guide future practice. Our review ranges widely across European countries as well as other high income countries, including Abu Dhabi, Japan and the USA, and other low and middle income Countries. There is a particular focus on Scotland, building on previous publications. We conclude based on multiple publications, including several case studies, that achieving efficiency in pharmaceutical spending is possible in virtually all environments, although there are examples of technologies where generic or therapeutic substitution should not be encouraged. However, there is no magic bullet to achieving full and appropriate use of generics. Countries have to be prepared to use a number of different education, economic, engineering and enforcement methods including prescribing restrictions to achieve success. Similarly, different approaches to achieve low prices for good quality generics given the considerable price differences that currently exist. The combination of low prices and increased use of generics will help achieve or attain universal healthcare, benefiting all key stakeholder groups. We conclude with a call for greater cross-country learning in pursuit of what should be a common goal for all health systems.

KW - co-payments

KW - compulsory substitution

KW - Scotland

KW - reforms

KW - prices

KW - generics

KW - prescribing restrictions

UR - http://journals.ke-i.org/index.php/mra/article/view/1071

U2 - 10.18103/mra.v5i3.1071

DO - 10.18103/mra.v5i3.1071

M3 - Article

VL - 5

JO - Medical Research Archives

JF - Medical Research Archives

SN - 2375-1916

IS - 3

ER -